MENU
Showcases Stock ranks Forex

Reata Pharma (RETA)
24.06  -11.64 (-32.61%) 08-08 16:00
Open: 27.02 Pre. Close: 35.7
High: 27.4988 Low: 21.79
Volume: 3,644,860 Market Cap: 877M
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 27.522 - 27.661 27.661 - 27.75
Low: 21.52 - 21.67 21.67 - 21.766
Close: 23.824 - 24.072 24.072 - 24.231
Stock Technical Analysis
Overall:     
Target: Six months: 37.52
One year: 44.97
Support: Support1: 21.79
Support2: 18.13
Resistance: Resistance1: 32.12
Resistance2: 38.51
Pivot: 31.72
Moving Averages: MA(5): 31.90
MA(20): 32.55
MA(100): 31.21
MA(250): 52.46
MACD: MACD(12,26): -0.56
Signal(12,26,9): -0.20
%K %D: %K(14,3): 61.73
%D(3): 64.10
RSI: RSI(14): 33.75
52-Week: High: 116.045
Low: 20.235
Change(%): -77.4
Average Vol(K): 3-Month: 451
10-Days: 635
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.

[ RETA ] has closed below the lower bollinger band by 16.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ RETA ] is to continue within current trading range. Bollinger Bands are 25.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Mon, 08 Aug 2022
Healthcare Stocks Making Moves Monday: KRTX, HSCS, CINC, SRGA, RETA, QURE, AXDX, GTHX - InvestorsObserver

Mon, 08 Aug 2022
Why Reata Pharma (RETA) Stock Is Plunging Today - Benzinga

Mon, 08 Aug 2022
CinCor, Karuna top healthcare gainers; Reata, uniQure lead losers' pack - Seeking Alpha

Mon, 08 Aug 2022
Reata Pharma falls 22% on Q2 revenue miss - Seeking Alpha

Mon, 08 Aug 2022
Reata Pharma Tops Q2 EPS by 75c By Investing.com - Investing.com India

Thu, 28 Jul 2022
Even though Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) stock is down 11% this week, insiders who bought lately made a US$66k profit - Simply Wall St

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 31.54
% Held by Insiders 28330000.00
% Held by Institutions 4.07
Shares Short (K) 4920
Shares Short Prior Month (K)
Stock Financials
EPS -252600000.000
Book Value (p.s.)
Profit Margin
Operating Margin -2.00
Return on Assets (ttm) 214.9
Return on Equity (ttm) -21.2
Qtrly Rev. Growth 11460000.0
Gross Profit (p.s.) -2.936
Sales Per Share -112.119
EBITDA (p.s.) -132568800.000
Qtrly Earnings Growth -8.35
Operating Cash Flow (M)
Levered Free Cash Flow (M) -248.88
Stock Valuation
PE Ratio
PEG Ratio
Price to Book value
Price to Sales -0.22
Price to Cash Flow 7.47
Stock Dividends
Dividend
Dividend Yield
Dividend Growth 5030000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android